CAS 2113650-03-4

BMS-1001

Description:

BMS-1001, identified by its CAS number 2113650-03-4, is a chemical compound that has garnered attention in pharmaceutical research, particularly in the context of its potential therapeutic applications. While specific characteristics such as molecular structure, physical properties, and biological activity may vary, compounds in this category are typically evaluated for their efficacy, safety, and mechanism of action. BMS-1001 may exhibit properties such as solubility in various solvents, stability under specific conditions, and a defined pharmacokinetic profile. Its development is likely aimed at targeting specific biological pathways or conditions, making it a candidate for further studies in drug formulation and clinical trials. As with any chemical substance, understanding its characteristics involves comprehensive analysis through techniques such as spectroscopy, chromatography, and biological assays to elucidate its behavior in biological systems and potential therapeutic benefits. For precise details, consulting scientific literature or databases would provide the most accurate and up-to-date information regarding BMS-1001.

Formula: C₃₅H₃₄N₂O₇

Synonyms:

• BMS-1001
• D-Serine, N-[[2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-5-methylphenyl]methyl]-

BMS-1001

CAS: 2113650-03-4

BMS-1001

Purity: ≥98%

Molecular weight: 594.7g/mol

Ref: 54-BUP08612

BMS-1001

CAS: 2113650-03-4

BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).

Formula: C₃₅H₃₄N₂O₇

Purity: 98.43%

Color and Shape: Solid

Molecular weight: 594.7

Ref: TM-T8470

BMS-1001

CAS: 2113650-03-4

BMS-1001 is a monoclonal antibody that targets the death protein (DR5). DR5 is an oncogenic receptor that binds to the tumor necrosis factor receptor 1 (TNFR1) and activates NF-κB signaling. The activation of TNFR1 induces the production of proinflammatory cytokines, which contribute to the development of cancer. BMS-1001 has been shown to inhibit tumor growth in animal models by inhibiting TNFR1 signaling, without inducing any adverse effects. It has also been shown to induce tumor regression in patients with metastatic melanoma, prostate cancer, and lung cancer. In addition, BMS-1001 has been shown to be active against other types of cancers such as pancreatic cancer, colorectal cancer, and glioblastoma

Formula: C₃₅H₃₄N₂O₇

Purity: Min. 95%

Molecular weight: 594.65 g/mol

Ref: 3D-NJD65003